🟢 Eli Lilly is trading 4.77% up today after Q2 earnings beat and raised 2026 revenue guidance

Eli Lilly is trading 4.77% up now at ARS 32940 after strong second-quarter results and higher full-year revenue guidance.

• Q2 revenue reached $23.0 billion, up 48% year over year, while adjusted EPS was $8.38.
• Management raised 2026 revenue guidance to $85 billion–$87 billion, from $82 billion–$85 billion previously.
• Strong Mounjaro and Zepbound demand, plus positive oncology developments, reinforced the bullish reaction.